Yifan Pharmaceutical Co., Ltd. (002019.SZ)
CNY 11.38
(0.53%)
CNY 11.38
(0.53%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 3.14 Billion CNY | -7.43% |
| 2022 | 3.39 Billion CNY | 0.2% |
| 2021 | 3.39 Billion CNY | 16.63% |
| 2020 | 2.9 Billion CNY | -10.39% |
| 2019 | 3.24 Billion CNY | 12.36% |
| 2018 | 2.88 Billion CNY | 45.42% |
| 2017 | 1.98 Billion CNY | -35.6% |
| 2016 | 3.08 Billion CNY | 85.03% |
| 2015 | 1.66 Billion CNY | 110.58% |
| 2014 | 791.21 Million CNY | 42.99% |
| 2013 | 553.34 Million CNY | -4.72% |
| 2012 | 580.72 Million CNY | -16.65% |
| 2011 | 696.73 Million CNY | 39.97% |
| 2010 | 497.78 Million CNY | 118.99% |
| 2009 | 227.31 Million CNY | -20.35% |
| 2008 | 285.39 Million CNY | -15.03% |
| 2007 | 335.87 Million CNY | 25.36% |
| 2006 | 267.91 Million CNY | 36.68% |
| 2005 | 196.01 Million CNY | 302.32% |
| 2004 | 48.72 Million CNY | -53.48% |
| 2003 | 104.72 Million CNY | 99.37% |
| 2002 | 52.52 Million CNY | 49.85% |
| 2001 | 35.05 Million CNY | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 3.59 Billion CNY | 4.8% |
| 2024 Q1 | 3.43 Billion CNY | 9.13% |
| 2024 Q3 | 3.95 Billion CNY | 9.83% |
| 2023 FY | 3.14 Billion CNY | -7.43% |
| 2023 Q2 | 3.29 Billion CNY | -3.75% |
| 2023 Q3 | 3.08 Billion CNY | -6.5% |
| 2023 Q4 | 3.14 Billion CNY | 2.09% |
| 2023 Q1 | 3.42 Billion CNY | 0.76% |
| 2022 Q1 | 3.62 Billion CNY | 6.83% |
| 2022 Q3 | 3.57 Billion CNY | 0.89% |
| 2022 FY | 3.39 Billion CNY | 0.2% |
| 2022 Q2 | 3.53 Billion CNY | -2.27% |
| 2022 Q4 | 3.39 Billion CNY | -4.88% |
| 2021 Q1 | 3.23 Billion CNY | 11.22% |
| 2021 Q4 | 3.39 Billion CNY | 9.42% |
| 2021 FY | 3.39 Billion CNY | 16.63% |
| 2021 Q2 | 3.15 Billion CNY | -2.41% |
| 2021 Q3 | 3.09 Billion CNY | -1.79% |
| 2020 Q3 | 3.31 Billion CNY | -0.08% |
| 2020 Q1 | 3.4 Billion CNY | 5.09% |
| 2020 FY | 2.9 Billion CNY | -10.39% |
| 2020 Q2 | 3.31 Billion CNY | -2.72% |
| 2020 Q4 | 2.9 Billion CNY | -12.28% |
| 2019 Q4 | 3.24 Billion CNY | 20.45% |
| 2019 Q3 | 2.69 Billion CNY | -6.63% |
| 2019 FY | 3.24 Billion CNY | 12.36% |
| 2019 Q1 | 2.68 Billion CNY | -6.94% |
| 2019 Q2 | 2.88 Billion CNY | 7.37% |
| 2018 Q4 | 2.88 Billion CNY | 22.45% |
| 2018 Q1 | 1.98 Billion CNY | 0.05% |
| 2018 FY | 2.88 Billion CNY | 45.42% |
| 2018 Q2 | 1.89 Billion CNY | -4.45% |
| 2018 Q3 | 2.35 Billion CNY | 24.23% |
| 2017 FY | 1.98 Billion CNY | -35.6% |
| 2017 Q3 | 2.38 Billion CNY | -13.07% |
| 2017 Q2 | 2.74 Billion CNY | 1.25% |
| 2017 Q1 | 2.71 Billion CNY | -11.97% |
| 2017 Q4 | 1.98 Billion CNY | -16.88% |
| 2016 FY | 3.08 Billion CNY | 85.03% |
| 2016 Q1 | 1.78 Billion CNY | 7.11% |
| 2016 Q2 | 2.97 Billion CNY | 66.84% |
| 2016 Q4 | 3.08 Billion CNY | -1.13% |
| 2016 Q3 | 3.11 Billion CNY | 4.73% |
| 2015 Q4 | 1.66 Billion CNY | 37.8% |
| 2015 Q3 | 1.2 Billion CNY | 16.57% |
| 2015 Q2 | 1.03 Billion CNY | 31.5% |
| 2015 Q1 | 788.8 Million CNY | -0.3% |
| 2015 FY | 1.66 Billion CNY | 110.58% |
| 2014 Q4 | 791.21 Million CNY | 0.94% |
| 2014 Q3 | 783.81 Million CNY | 45.82% |
| 2014 Q1 | 548.16 Million CNY | -0.94% |
| 2014 Q2 | 537.51 Million CNY | -1.94% |
| 2014 FY | 791.21 Million CNY | 42.99% |
| 2013 FY | 553.34 Million CNY | -4.72% |
| 2013 Q4 | 553.34 Million CNY | -0.26% |
| 2013 Q3 | 554.77 Million CNY | 0.17% |
| 2013 Q2 | 553.84 Million CNY | -4.93% |
| 2013 Q1 | 582.54 Million CNY | 0.31% |
| 2012 FY | 580.72 Million CNY | -16.65% |
| 2012 Q2 | 558.81 Million CNY | -21.43% |
| 2012 Q4 | 580.72 Million CNY | 14.26% |
| 2012 Q3 | 508.27 Million CNY | -9.04% |
| 2012 Q1 | 711.19 Million CNY | 2.08% |
| 2011 Q2 | 583.01 Million CNY | 5.03% |
| 2011 Q4 | 696.73 Million CNY | 17.16% |
| 2011 Q3 | 594.67 Million CNY | 2.0% |
| 2011 Q1 | 555.09 Million CNY | 11.51% |
| 2011 FY | 696.73 Million CNY | 39.97% |
| 2010 Q2 | 419.76 Million CNY | 50.33% |
| 2010 Q4 | 497.78 Million CNY | 13.36% |
| 2010 Q3 | 439.13 Million CNY | 4.61% |
| 2010 FY | 497.78 Million CNY | 118.99% |
| 2010 Q1 | 279.22 Million CNY | 22.84% |
| 2009 Q1 | 308.28 Million CNY | 8.02% |
| 2009 Q4 | 227.31 Million CNY | -33.24% |
| 2009 FY | 227.31 Million CNY | -20.35% |
| 2009 Q2 | 309.96 Million CNY | 0.55% |
| 2009 Q3 | 340.48 Million CNY | 9.84% |
| 2008 FY | 285.39 Million CNY | -15.03% |
| 2008 Q3 | 292.93 Million CNY | -9.79% |
| 2008 Q2 | 324.72 Million CNY | 5.41% |
| 2008 Q1 | 308.07 Million CNY | -8.28% |
| 2008 Q4 | 285.39 Million CNY | -2.57% |
| 2007 Q2 | 282.11 Million CNY | 11.28% |
| 2007 Q1 | 253.51 Million CNY | -5.38% |
| 2007 Q3 | 302.07 Million CNY | 7.08% |
| 2007 Q4 | 335.87 Million CNY | 11.19% |
| 2007 FY | 335.87 Million CNY | 25.36% |
| 2006 Q1 | 199.34 Million CNY | 1.7% |
| 2006 Q3 | 229.63 Million CNY | 7.6% |
| 2006 FY | 267.91 Million CNY | 36.68% |
| 2006 Q4 | 267.91 Million CNY | 16.67% |
| 2006 Q2 | 213.42 Million CNY | 7.06% |
| 2005 FY | 196.01 Million CNY | 302.32% |
| 2005 Q1 | 109.58 Million CNY | 124.92% |
| 2005 Q2 | 156.09 Million CNY | 42.44% |
| 2005 Q3 | 188.88 Million CNY | 21.01% |
| 2005 Q4 | 196.01 Million CNY | 3.78% |
| 2004 FY | 48.72 Million CNY | -53.48% |
| 2004 Q3 | 65.29 Million CNY | -44.97% |
| 2004 Q2 | 118.65 Million CNY | 0.0% |
| 2004 Q4 | 48.72 Million CNY | -25.39% |
| 2003 FY | 104.72 Million CNY | 99.37% |
| 2003 Q4 | 104.72 Million CNY | 0.0% |
| 2002 FY | 52.52 Million CNY | 49.85% |
| 2001 FY | 35.05 Million CNY | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Zhejiang Int'l Group Co.,Ltd. | 9.12 Billion CNY | 65.545% |
| Zhejiang Zhenyuan Share Co., Ltd. | 974.86 Million CNY | -222.603% |
| Hunan Jingfeng Pharmaceutical Co.,Ltd. | 1.21 Billion CNY | -159.05% |
| Hubei Guangji Pharmaceutical Co., Ltd. | 1.63 Billion CNY | -92.108% |
| Guangdong Jiaying Pharmaceutical Co., Ltd | 84.57 Million CNY | -3618.363% |
| Sichuan Kelun Pharmaceutical Co., Ltd. | 13.22 Billion CNY | 76.212% |
| Chongqing Lummy Pharmaceutical Co., Ltd. | 762.32 Million CNY | -312.547% |
| Boai NKY Medical Holdings Ltd. | 499.66 Million CNY | -529.414% |
| Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. | 258.46 Million CNY | -1116.796% |